Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.14.5 extracted from

  • Coumar, M.S.; Chang, C.N.; Chen, C.T.; Chen, X.; Chien, C.H.; Tsai, T.Y.; Cheng, J.H.; Wu, H.Y.; Han, C.H.; Wu, S.H.; Huang, Y.W.; Hsu, T.; Hsu, L.J.; Chao, Y.S.; Hsieh, H.P.; Jiaang, W.T.
    3-[2-((2S)-2-Cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes (2007), Bioorg. Med. Chem. Lett., 17, 1274-1279.
    View publication on PubMed

Inhibitors

Inhibitors Comment Organism Structure
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-N-(3,4-dimethoxyphenyl)-3-methylbutanamide in vivo efficacy in rat models after oral administration. The inhibitor has potential for further development as antidiabetic agent Rattus norvegicus
N3-[2-[(2S)-2-cyanopyrrolidin-1-yl]-1,1-dimethyl-2-oxoethyl]-N-(2-pyridin-2-ylethyl)-b-alaninamide in vivo efficacy in rat models after oral administration Rattus norvegicus

Organism

Organism UniProt Comment Textmining
Rattus norvegicus
-
-
-

Synonyms

Synonyms Comment Organism
DPP-IV
-
Rattus norvegicus